Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $55.38 Consensus Price Target from Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have been given an average recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $55.38.

A number of analysts recently weighed in on the stock. UBS Group assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, February 13th. They set a “buy” rating and a $44.00 price target for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $67.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research report on Friday, February 28th. Finally, The Goldman Sachs Group decreased their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd.

Celldex Therapeutics Stock Up 1.4 %

Shares of NASDAQ CLDX opened at $20.42 on Thursday. Celldex Therapeutics has a 52-week low of $18.61 and a 52-week high of $47.00. The firm has a fifty day moving average of $22.85 and a 200-day moving average of $27.86. The stock has a market capitalization of $1.36 billion, a PE ratio of -7.95 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million during the quarter, compared to analysts’ expectations of $1.25 million. Equities research analysts expect that Celldex Therapeutics will post -2.48 EPS for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in CLDX. EverSource Wealth Advisors LLC boosted its position in Celldex Therapeutics by 215.7% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 878 shares during the last quarter. KBC Group NV raised its stake in shares of Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after purchasing an additional 495 shares in the last quarter. Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at about $81,000. AlphaQuest LLC raised its stake in shares of Celldex Therapeutics by 171.0% in the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 2,705 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Celldex Therapeutics in the 4th quarter valued at about $121,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.